Rationale and design of the randomised controlled cross-over trial: Cardiovascular effects of empaglifozin in diabetes mellitus

BACKGROUND: Type 2 diabetes (T2D) is associated with an increased risk of cardiovascular (CV) disease. In patients with T2D and established CV disease, selective inhibitors of sodium–glucose cotransporter 2 (SGLT2) have been shown to decrease CV and all-cause mortality, and heart failure (HF) admiss...

Descripción completa

Detalles Bibliográficos
Autores principales: Thirunavukarasu, Sharmaine, Brown, Louise AE, Chowdhary, Amrit, Jex, Nicholas, Swoboda, Peter, Greenwood, John P, Plein, Sven, Levelt, Eylem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481726/
https://www.ncbi.nlm.nih.gov/pubmed/34182806
http://dx.doi.org/10.1177/14791641211021585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481726/
https://www.ncbi.nlm.nih.gov/pubmed/34182806
http://dx.doi.org/10.1177/14791641211021585

Ejemplares similares